Drug Trial Radar · NCT07284043
A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism
Last checked: Nov 19, 2026Latest source record: Jul 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
6
Actual
Start
Nov 27, 2025
Primary completion
May 14, 2026
Study completion May 14, 2026
Sponsor
- Lead sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Dec 16, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of \[14C\] MT1013.
Conditions
- Hemodialysis Subjects With Secondary Hyperparathyroidism
Interventions
[14C] MT1013/MT1013 InjectionDrug
\[14C\] MT1013/MT1013 Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Cumulative excretion of radioactivityTime frame: Day 1 to Day 91.
- Percentage of parent drug and its metabolites in plasma as a percentage of total radioactive exposure (%AUC)Time frame: Day 1 to Day 91.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Shandong First Medical University (Shandong Qianfoshan Hospital)
Jinan, Shandong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.